Zacks Investment Research upgraded shares of Catabasis Pharmaceuticals (NASDAQ:CATB) from a hold rating to a buy rating in a research note issued to investors on Thursday morning. Zacks Investment Research currently has $1.75 target price on the biotechnology company’s stock.

According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Several other research analysts also recently commented on CATB. Citigroup reaffirmed a hold rating and issued a $1.50 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, September 29th. Oppenheimer raised their price target on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an outperform rating in a research note on Thursday, October 5th. CIBC reaffirmed an outperform rating and issued a $7.00 price target (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a research note on Thursday, October 5th. Cowen reaffirmed a market perform rating and issued a $2.00 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, October 6th. Finally, Wedbush reaffirmed an outperform rating and issued a $4.00 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, December 15th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $4.82.

Catabasis Pharmaceuticals (CATB) traded down $0.02 during trading on Thursday, hitting $1.54. 274,447 shares of the stock traded hands, compared to its average volume of 207,614. The company has a market cap of $35.55 and a price-to-earnings ratio of -1.02. Catabasis Pharmaceuticals has a 12-month low of $1.08 and a 12-month high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.25 million during the quarter. analysts anticipate that Catabasis Pharmaceuticals will post -1.38 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of CATB. Oppenheimer & Co. Inc. increased its stake in Catabasis Pharmaceuticals by 33.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock worth $169,000 after buying an additional 30,000 shares during the period. Virtu KCG Holdings LLC purchased a new position in Catabasis Pharmaceuticals during the 2nd quarter valued at about $271,000. Finally, Wedbush Securities Inc. increased its position in Catabasis Pharmaceuticals by 2,368.6% during the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after purchasing an additional 241,602 shares during the period. 32.31% of the stock is currently owned by institutional investors.

WARNING: “Catabasis Pharmaceuticals (CATB) Raised to Buy at Zacks Investment Research” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/15/catabasis-pharmaceuticals-catb-raised-to-buy-at-zacks-investment-research.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get a free copy of the Zacks research report on Catabasis Pharmaceuticals (CATB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Stock Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related stocks with our FREE daily email newsletter.